Therapy Detail

Therapy Name MCLA-128
Therapy Description

MCLA-128 is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MCLA-128 MCLA-128 is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable MCLA-128 Phase Ib/II Actionable In a Phase I/II trial, MCLA-128 demonstrated safety and preliminary efficacy, resulted in partial response in 3.6% (1/28) and stable disease in 7.1% (2/28) of patients with advanced solid tumors (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown colorectal cancer not applicable MCLA-128 Phase Ib/II Actionable In a Phase I/II trial, MCLA-128 resulted in stable disease for 5 months in a patient with colorectal cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown gastroesophageal junction adenocarcinoma not applicable MCLA-128 Phase Ib/II Actionable In a Phase I/II trial, MCLA-128 resulted in stable disease for 5 months in a patient with gastroesophageal junction cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Unknown unknown non-small cell lung carcinoma not applicable MCLA-128 Phase Ib/II Actionable In a Phase I/II trial, MCLA-218 resulted in partial response for more than 10 months in a patient with non-small cell lung cancer (Cancer Res 2016;76(14 Suppl):Abstract nr CT050). detail...
Clinical Trial Phase Therapies Title Recruitment Status